Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial

静脉切开术 医学 海西定 血色病 内科学 胃肠病学 遗传性血色病 贫血
作者
Kris V. Kowdley,Nishit B. Modi,Kevork Peltekian,John M. Vierling,Christopher D. Ferris,Frank H. Valone,Suneel Gupta
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:8 (12): 1118-1128 被引量:22
标识
DOI:10.1016/s2468-1253(23)00250-9
摘要

Hereditary haemochromatosis protein (HFE)-related haemochromatosis, an inherited iron overload disorder caused by insufficient hepcidin production, results in excessive iron absorption and tissue and organ injury, and is treated with first-line therapeutic phlebotomy. We aimed to investigate the efficacy and safety of rusfertide, a peptidic mimetic of hepcidin, in patients with HFE-related haemochromatosis.This open-label, multicentre, proof-of-concept phase 2 trial was done across nine academic and community centres in the USA and Canada. Adults (aged ≥18 years) with HFE-related haemochromatosis on a stable therapeutic phlebotomy regimen (maintenance phase) for at least 6 months before screening and who had a phlebotomy frequency of at least 0·25 per month (eg, at least three phlebotomies in 12 months or at least four phlebotomies in 15 months) and less than one phlebotomy per month, with serum ferritin of less than 300 ng/mL and haemoglobin of more than 11·5 g/dL, were eligible. Patients initiated 24 weeks of subcutaneous rusfertide treatment within 7 days of a scheduled phlebotomy at 10 mg once weekly. Rusfertide doses and dosing schedules could be adjusted to maintain serum transferrin iron saturation (TSAT) at less than 40%. During rusfertide treatment, investigators were to consider the need for phlebotomy when the serum ferritin and TSAT values exceeded the patient's individual pre-phlebotomy serum ferritin and TSAT values. No primary endpoint or testing hierarchy was prespecified. Prespecified efficacy endpoints included the change in the frequency of phlebotomies; the proportion of patients achieving phlebotomy independence; change in serum iron, TSAT, serum transferrin, serum ferritin, and liver iron concentration (LIC) as measured by MRI; and treatment-emergent adverse events (TEAEs). The key efficacy analyses for phlebotomy rate and LIC were conducted by use of paired t tests in the intention-to-treat population, defined as all patients who received any study drug and who had pretreatment and at least one post-dose measurement. We included all participants who received at least one dose of rusfertide in the safety analyses. This trial is closed and completed and is registered with ClinicalTrials.gov, NCT04202965.Between March 11, 2020, and April 23, 2021, 28 patients were screened and 16 (ten [63%] men and six [38%] women) were enrolled. 16 were included in analyses of phlebotomy endpoints and 14 for the LIC endpoint. 12 (75%) patients completed 24 weeks of treatment. The mean number of phlebotomies was significantly reduced during the 24-week rusfertide treatment (0·06 phlebotomies [95% CI -0·07 to 0·20]) compared with 24 weeks pre-study (2·31 phlebotomies [95% CI 1·77 to 2·85]; p<0·0001). 15 (94%) of 16 patients were phlebotomy-free during the treatment period. Mean LIC in the 14 patients in the intention-to-treat population was 1·4 mg iron per g dry liver weight (95% CI 1·0 to 1·8) at screening and 1·1 mg iron per g dry liver weight (95% CI 0·9 to 1·3) at the end of treatment (p=0·068). Mean TSAT was 45·3% (95% CI 33·2 to 57·3) at screening, 36·7% (24·2 to 49·2) after the pretreatment phlebotomy, 21·8% (15·8 to 27·9) 24 h after the first dose of rusfertide, 40·4% (27·1 to 53·8) at the end of treatment, and 32·6% (25·0 to 40·1) over the treatment duration. Mean serum iron was 24·6 μmol/L (95% CI 18·6 to 30·6), 20·1 μmol/L (14·8 to 25·3), 11·9 μmol/L (9·2 to 14·7), 22·5 μmol/L (15·9 to 29·1), and 19·0 μmol/L (15·3 to 22·6) at these same timepoints, respectively. Mean serum ferritin was 83·3 μg/L (52·2 to 114.4), 65·5 μg/L (32·1 to 98·9), 62·8 μg/L (33·8 to 91·9), 150·0 μg/L (86·6 to 213.3), and 94·3 μg/L (54·9 to 133.6) at these same timepoints, respectively. There were only minor changes in serum transferrin concentration. 12 (75%) patients had at least one TEAE, the most common of which was injection site pain (five [31%] patients). All TEAEs were mild or moderate in severity, except for a serious adverse event of pancreatic adenocarcinoma, which was considered severe and unrelated to treatment and was pre-existing and diagnosed 21 days after starting rusfertide treatment.Rusfertide prevents iron re-accumulation in the absence of phlebotomies and could be a viable therapeutic option for selected patients with haemochromatosis.Protagonist Therapeutics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
时势造英雄完成签到 ,获得积分10
1秒前
沟通亿心完成签到,获得积分10
1秒前
传奇3应助无心的雅旋采纳,获得10
1秒前
满意代萱完成签到 ,获得积分10
2秒前
dream完成签到 ,获得积分10
4秒前
芙瑞完成签到 ,获得积分10
4秒前
4秒前
xliiii完成签到,获得积分10
6秒前
纯爱完成签到,获得积分10
8秒前
阿米尔灿发布了新的文献求助10
10秒前
sdfdzhang完成签到 ,获得积分0
11秒前
12秒前
Zurlliant完成签到,获得积分10
13秒前
星辰大海应助舍弃采纳,获得10
14秒前
14秒前
15秒前
英俊的铭应助阿米尔灿采纳,获得10
15秒前
xyzlancet完成签到,获得积分10
15秒前
吴建文发布了新的文献求助10
16秒前
七月完成签到,获得积分10
16秒前
张张张xxx完成签到,获得积分10
16秒前
美女完成签到,获得积分10
19秒前
19秒前
卞卞发布了新的文献求助10
20秒前
无花果应助Hanguo采纳,获得10
21秒前
量子星尘发布了新的文献求助10
22秒前
huahua完成签到 ,获得积分10
22秒前
热心不凡完成签到,获得积分10
23秒前
zhang完成签到 ,获得积分10
23秒前
JUAN完成签到,获得积分10
23秒前
秦磊发布了新的文献求助10
23秒前
真实的采白完成签到 ,获得积分10
26秒前
cuddly完成签到 ,获得积分10
27秒前
时舒完成签到 ,获得积分10
27秒前
maxthon完成签到,获得积分10
27秒前
美女发布了新的文献求助10
27秒前
hehe完成签到,获得积分10
28秒前
afar完成签到 ,获得积分10
29秒前
守望阳光1完成签到,获得积分10
31秒前
哇哇哇哇完成签到,获得积分10
32秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Social Research Methods (4th Edition) by Maggie Walter (2019) 2390
A new approach to the extrapolation of accelerated life test data 1000
北师大毕业论文 基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 390
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4008786
求助须知:如何正确求助?哪些是违规求助? 3548464
关于积分的说明 11298867
捐赠科研通 3283080
什么是DOI,文献DOI怎么找? 1810290
邀请新用户注册赠送积分活动 886000
科研通“疑难数据库(出版商)”最低求助积分说明 811220